Home › Compare › JPPHY vs ABBV
JPPHY yields 2.61% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, JPPHY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JPPHY + ABBV for your $10,000?
Japan Post Holdings Co., Ltd. provides postal, banking, and insurance services in Japan. The company engages in the postal, banking counter, and insurance counter operations; sale of documentary stamps, petroleum, and catalog products; operations consigned by local government entities; and provision of other bank, and life and non-life insurance agency services. It also provides distribution and delivery; and merchandise sale services, as well as international cargo transport and agency services. In addition, the company offers Yu-Pack, Yu-Mail, and other parcel delivery; deposits, securities investment, remittances, credit card, and personal loans; road, rail, ship, and air transportation; freight forwarding and other logistics; and asset management services. Further, it provides truck cargo transportation, automobile and machinery maintenance, vehicle maintenance and management, post office advertisements posting, automobile liability insurance agency, 3PL, and express services. Additionally, it provides contracting, hotel management, and management, investment, financial and management consulting, and telemarketing services. The company also engages in the planning, development, and sale of direct mail; and commissioning of design, development, maintenance, and operation of information systems. In addition, it owns, leases, and manages real estate; develops residential and commercial land; consults, plans and develops business systems and basic technologies; and operates 3 Teishin hospitals, MIELPARQUE hotels, and 35 Kanpo no Yado inns in Japan. Japan Post Holdings Co., Ltd. was founded in 1871 and is headquartered in Tokyo, Japan.
Full JPPHY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.